SG11201407752YA - Pyrrolo[2,1-f][1,2,4]triazine compound, and preparation method and application thereof - Google Patents

Pyrrolo[2,1-f][1,2,4]triazine compound, and preparation method and application thereof

Info

Publication number
SG11201407752YA
SG11201407752YA SG11201407752YA SG11201407752YA SG11201407752YA SG 11201407752Y A SG11201407752Y A SG 11201407752YA SG 11201407752Y A SG11201407752Y A SG 11201407752YA SG 11201407752Y A SG11201407752Y A SG 11201407752YA SG 11201407752Y A SG11201407752Y A SG 11201407752YA
Authority
SG
Singapore
Prior art keywords
shanghai
lllll
pyrrolo
triazine compound
llll
Prior art date
Application number
SG11201407752YA
Other languages
English (en)
Inventor
Chunhao Yang
Linghua Meng
Yanhong Chen
Xiang Wang
Cun Tan
Jiapeng Li
Jian Ding
Yi Chen
Original Assignee
Shanghai Inst Materia Medica
Shanghai Haihe Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Inst Materia Medica, Shanghai Haihe Pharmaceutical Co Ltd filed Critical Shanghai Inst Materia Medica
Publication of SG11201407752YA publication Critical patent/SG11201407752YA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
SG11201407752YA 2012-05-31 2013-04-23 Pyrrolo[2,1-f][1,2,4]triazine compound, and preparation method and application thereof SG11201407752YA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201210177980.3A CN103450204B (zh) 2012-05-31 2012-05-31 吡咯[2，1-f][1，2，4]并三嗪类化合物，其制备方法及用途
PCT/CN2013/074559 WO2013177983A1 (zh) 2012-05-31 2013-04-23 吡咯[2，1-f][1，2，4]并三嗪类化合物，其制备方法及用途

Publications (1)

Publication Number Publication Date
SG11201407752YA true SG11201407752YA (en) 2015-01-29

Family

ID=49672377

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201407752YA SG11201407752YA (en) 2012-05-31 2013-04-23 Pyrrolo[2,1-f][1,2,4]triazine compound, and preparation method and application thereof

Country Status (14)

Country Link
US (1) US9447101B2 (ja)
EP (1) EP2857403B1 (ja)
JP (1) JP6067107B2 (ja)
KR (1) KR101824299B1 (ja)
CN (1) CN103450204B (ja)
AU (1) AU2013270326B2 (ja)
BR (1) BR112014029708B1 (ja)
CA (1) CA2874062C (ja)
ES (1) ES2703934T3 (ja)
HK (1) HK1203499A1 (ja)
MX (1) MX359207B (ja)
RU (1) RU2589053C1 (ja)
SG (1) SG11201407752YA (ja)
WO (1) WO2013177983A1 (ja)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9724352B2 (en) * 2012-05-31 2017-08-08 Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences Pyrrolo[2,1-F[1,2,4]triazine compounds, preparation methods and applications thereof
EP2948454B1 (en) 2013-01-24 2017-05-31 Council of Scientific & Industrial Research An Indian registered body incorporated under the Registration of Societies Act (Act XXI of 1860) Triazine compounds and a process for preparation thereof
US10214537B2 (en) 2014-10-22 2019-02-26 Bristol-Myers Squibb Company Bicyclic heteroaryl amine compounds
EP3209665B1 (en) 2014-10-22 2019-08-14 Bristol-Myers Squibb Company Substituted pyrrolotriazine amine compounds as pi3k inhibitors
WO2017004134A1 (en) * 2015-06-29 2017-01-05 Nimbus Iris, Inc. Irak inhibitors and uses thereof
WO2017040448A1 (en) * 2015-08-31 2017-03-09 Bristol-Myers Squibb Company Tgf beta receptor antagonists
CN109641909B (zh) 2016-06-25 2022-01-11 苏州开拓药业股份有限公司 雷帕霉素信号通路抑制剂的机理靶标及其治疗应用
CN109111447A (zh) * 2017-06-23 2019-01-01 中国科学院上海药物研究所 7-位取代吡咯并三嗪类化合物或其药学上可用的盐，及其制备方法和用途
EP3670513B1 (en) * 2017-08-15 2023-09-20 CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. Fgfr inhibitor and medical application thereof
GB201720989D0 (en) * 2017-12-15 2018-01-31 Glaxosmithkline Ip Dev Ltd Chemical compounds
CA3154079A1 (en) 2019-09-19 2021-03-25 Totus Medicines Inc. Therapeutic conjugates
CN112851563A (zh) * 2020-12-30 2021-05-28 安徽金鼎医药股份有限公司 N-氨基-3-氮杂双环[3,3,0]辛烷盐酸盐的合成工艺
TW202313056A (zh) * 2021-09-10 2023-04-01 大陸商上海海和藥物研究開發股份有限公司 包含ＰＩ３Ｋα抑制劑的藥物組合

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6867300B2 (en) 2000-11-17 2005-03-15 Bristol-Myers Squibb Company Methods for the preparation of pyrrolotriazine compounds useful as kinase inhibitors
TWI329112B (en) 2002-07-19 2010-08-21 Bristol Myers Squibb Co Novel inhibitors of kinases
TW200420565A (en) 2002-12-13 2004-10-16 Bristol Myers Squibb Co C-6 modified indazolylpyrrolotriazines
MY145634A (en) 2003-12-29 2012-03-15 Bristol Myers Squibb Co Pyrrolotriazine compounds as kinase inhibitors
US7713973B2 (en) 2004-10-15 2010-05-11 Takeda Pharmaceutical Company Limited Kinase inhibitors
US7151176B2 (en) 2004-10-21 2006-12-19 Bristol-Myers Squibb Company Pyrrolotriazine compounds
TW200635927A (en) 2004-12-22 2006-10-16 Bristol Myers Squibb Co Synthetic process
US7619083B2 (en) 2005-07-01 2009-11-17 Bristol-Myers Squibb Company Intermediates useful in preparing certain pyrrolotriazine compounds and process for making such intermediates
US7514435B2 (en) 2005-11-18 2009-04-07 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
KR101443400B1 (ko) 2006-07-07 2014-10-02 브리스톨-마이어스 스큅 컴퍼니 피롤로트리아진 키나제 억제제
EP2050749B1 (en) * 2006-08-08 2017-11-22 Chugai Seiyaku Kabushiki Kaisha Pyrimidine derivative as pi3k inhibitor and use thereof
JP5284977B2 (ja) * 2006-12-07 2013-09-11 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト ホスホイノシチド３−キナーゼ阻害剤化合物及び使用方法
US8148522B2 (en) 2007-01-02 2012-04-03 Bristol-Myers Squibb Company Intermediate useful in preparing certain pyrrolotriazine compounds and a process for making the intermediate
WO2008131050A1 (en) 2007-04-18 2008-10-30 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
US8124759B2 (en) 2007-05-09 2012-02-28 Abbott Laboratories Inhibitors of protein kinases
KR20100083170A (ko) * 2007-10-16 2010-07-21 와이어쓰 엘엘씨 티에노피리미딘 및 피라졸로피리미딘 화합물 및 이의 ｍＴＯＲ 키나제 및 ＰＩ3 키나제 억제제로서의 용도
CL2009000241A1 (es) * 2008-02-07 2010-09-03 Chugai Pharmaceutical Co Ltd Compuestos derivados de 5-(2-morfolin-4-il-7h-pirrolo[2,3-d]pirimidin-4-il)pirimidin-2-ilamina; proceso de preparacion; composicion farmaceutica; y uso de los compuestos para tratar o prevenir una enfermedad proliferativa tal como el cancer.
US20110269740A1 (en) 2008-07-02 2011-11-03 Ambit Biosciences Corporation Jak kinase modulating compounds and methods of use thereof
WO2010002954A1 (en) * 2008-07-02 2010-01-07 Wyeth (2-aryl-7h-pyrrolo[2,3-d]pyrimidin-4-yl)morpholine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses
WO2010092340A1 (en) * 2009-02-13 2010-08-19 Ucb Pharma S.A. Fused pyridine and pyrazine derivatives as kinase inhibitors
AU2010238361B2 (en) * 2009-04-16 2015-08-06 Fundacion Centro Nacional De Investigaciones Oncologicas Carlos Iii Imidazopyrazines for use as kinase inhibitors
CA2787714C (en) * 2010-01-22 2019-04-09 Joaquin Pastor Fernandez Inhibitors of pi3 kinase
WO2011141713A1 (en) * 2010-05-13 2011-11-17 Centro Nacional De Investigaciones Oncologicas (Cnio) New bicyclic compounds as pi3-k and mtor inhibitors
CN102675323B (zh) * 2012-06-01 2014-04-09 南京药石药物研发有限公司 吡咯并[2,1-f][1,2,4]三嗪衍生物及其抗肿瘤用途

Also Published As

Publication number Publication date
CN103450204B (zh) 2016-08-17
US9447101B2 (en) 2016-09-20
KR20150009565A (ko) 2015-01-26
JP2015518010A (ja) 2015-06-25
US20150141644A1 (en) 2015-05-21
AU2013270326B2 (en) 2016-07-14
MX2014014622A (es) 2015-08-10
ES2703934T3 (es) 2019-03-13
AU2013270326A1 (en) 2014-12-18
BR112014029708B1 (pt) 2023-05-02
EP2857403B1 (en) 2018-10-10
EP2857403A4 (en) 2015-10-21
CN103450204A (zh) 2013-12-18
WO2013177983A1 (zh) 2013-12-05
HK1203499A1 (en) 2015-10-30
RU2589053C1 (ru) 2016-07-10
BR112014029708A8 (pt) 2021-09-08
KR101824299B1 (ko) 2018-03-14
MX359207B (es) 2018-09-19
CA2874062A1 (en) 2013-12-05
EP2857403A1 (en) 2015-04-08
BR112014029708A2 (pt) 2017-06-27
JP6067107B2 (ja) 2017-01-25
CA2874062C (en) 2015-09-22

Similar Documents

Publication Publication Date Title
SG11201407752YA (en) Pyrrolo[2,1-f][1,2,4]triazine compound, and preparation method and application thereof
SG11201903182XA (en) 6,7,8,9-tetrahydro-3h-pyrazolo[4,3-f]isoquinoline derivatives useful in the treatment of cancer
SG11201804170RA (en) Polycyclic tlr7/8 antagonists and use thereof in the treatment of immune disorders
SG11201811549UA (en) Boronic acid derivatives and therapeutic uses thereof
SG11201900163PA (en) Macrocycle kinase inhibitors
SG11201810683VA (en) Process for preparing n-(5-(3-(7-(3-fluorophenyl)-3h-imidazo[4,5-c]pyridin-2-yl)-1h-indazol-5-yl)pyridin-3-yl)-3-methylbutanamide
SG11201811470PA (en) Pyrazolopyrimidine derivatives as kinase inhibitor
SG11201909022PA (en) ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF
SG11201408095XA (en) Fibroblast growth factor 21 proteins
SG11201810628XA (en) Nasal pharmaceutical compositions with a porous excipient
SG11201407228PA (en) N-aryltriazole compounds as lpar antagonists
SG11201808108XA (en) Synthesis of indazoles
SG11201406775UA (en) Injectable formulation
SG11201810371XA (en) ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF
SG11201407220YA (en) N-alkyltriazole compounds as lpar antagonists
SG11201907032RA (en) Amino pyrimidine compounds useful as ssao inhibitors
SG11201408617PA (en) Bifluorodioxalane-amino-benzimidazole kinase inhibitors for the treatment of cancer, autoimmuneinflammation and cns disorders
SG11201500005SA (en) Pyrimidine pyrazolyl derivatives
SG11201908602UA (en) Combination therapy for the treatment of solid and hematological cancers
SG11201807540UA (en) Novel compounds and pharmaceutical compositions thereof for the treatment of fibrosis
SG11201810965YA (en) 1h-pyrazolo[4,3-b]pyridines as pde1 inhibitors
SG11201809172WA (en) Crystalline forms of n-[2-(3-hydroxy-3-methylbutyl)-6-(2-hydroxypropan-2-yl)-2h-indazol-5-yl]-6-(trifluoromethyl)pyridine-2-carboxamide
SG11201408641UA (en) Phenoxyethyl piperidine compounds
SG11201407575PA (en) 5-amino[1,4]thiazines as bace 1 inhibitors
SG11201908097YA (en) Pyrimidine derivatives as pge2 receptor modulators